Comparison of biosimilar Tigerase and Pulmozyme in long-term symptomatic therapy of patients with cystic fibrosis and severe pulmonary impairment (subgroup analysis of a Phase III randomized open-label clinical trial (NCT04468100)).
2021 yr.
Attention!
This page contains information about prescription medications. According to the Russian regulatory requirements, this information can be available only for medical or pharmaceutical stuff.
Do you confirm that you are a medical of pharmaceutical specialist?
INN: dornase alfa
Recombinant human deoxyribonuclease I, a genetically engineered version of a natural human enzyme that cleaves extracellular DNA. The mechanism of the drug is the cleavage of extracellular DNA molecules that accumulate in bronchial secretions due to the breakdown of neutrophils, macrophages and bacterial cells and increase its viscosity.
Dornase alfa is the primary mucolytic drug for the treatment of cystic fibrosis.
The use of dornase alfa in patients with cystic fibrosis promotes:
Generium is the first company in the world to develop and produce dornase alpha biosimilar.
ЛП-005537 от 23.05.2019
Comparison of biosimilar Tigerase and Pulmozyme in long-term symptomatic therapy of patients with cystic fibrosis and severe pulmonary impairment (subgroup analysis of a Phase III randomized open-label clinical trial (NCT04468100)).
2021 yr.